

Escinosomes: Safe and Successful Nanovesicles to Deliver Andrographolide by a Subcutaneous Route in a Mice Model of Oxaliplatin-Induced Neuropathy

Giulia Vanti ¹, Michela Capizzi ¹, Lorenzo Di Cesare Mannelli ², Elena Lucarini ², Maria Camilla Bergonzi ¹, Carla Ghelardini ² and Anna Rita Bilia ^{1,*}

¹ Department of Chemistry, University of Florence, Via Ugo Schiff 6, 50019, Florence, Italy; giulia.vanti@unifi.it (G.V.); michela.capizzi@stud.unifi.it (M.C.); mc.bergonzi@unifi.it (M.C.B.)

² Pharmacology and Toxicology Section, Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Viale G. Pieraccini 6, 50139 Firenze, Italy; lorenzo.mannelli@unifi.it (L.D.C.M.); elena.lucarini@unifi.it (E.L.); carla.ghelardini@unifi.it (C.G.)

* Correspondence: ar.bilia@unifi.it; Tel.: +39-0554-573709

Table S1. Effect of the acute administration of AG-loaded escinosomes on oxaliplatin-induced behavioral, autonomic, and neurological alterations by Irwin test. The Irwin test was performed 30 minutes following the acute administration of the treatments in oxaliplatin-treated rats. The signs were evaluated semi-quantitatively, according to the observer's personal scale (0 to +4, −4 to 0, or −4 to +4). Each value represents the mean ± SEM of 5 rats per group. **p* < 0.05 vs vehicle + vehicle group.

Treatments						
	Vehicle + Vehicle	OX + Vehicle	OX + AG-Esc 10 mg/kg	OX + AG 10 mg/kg	OX + Esc	Limits
Behavior						
Spontaneous activity	4 ± 0	2.3 ± 0.2*	2.1 ± 0.1	2.4 ± 0.2	2.0 ± 0.2	4–0
Passivity	0 ± 0	2.0 ± 0.1*	1.9 ± 0.2	2.0 ± 0.2	2.2 ± 0.1	0–4
Cleaning	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4–0
Curiosity	4 ± 0	2.5 ± 0.2*	2.3 ± 0.1	2.3 ± 0.1	2.6 ± 0.2	4–0
Reactivity	4 ± 0	2.2 ± 0.1*	2.0 ± 0.2	2.3 ± 0.1	2.4 ± 0.1	4–0
Vocalization	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Central Nervous System Excitement						
Straub tail	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Tremors	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Convulsions	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	4–0
Movement						
Ataxia	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Stereotypies	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Straightening reflex	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4–0
Muscular Tone						
Physical strength	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4–0
Palpebral reflex	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4–0
Autonomic Signs						
Piloerection	0 ± 0	2.6 ± 0.1*	2.7 ± 0.1	2.5 ± 0.1	2.5 ± 0.2	0–4
Exophthalmos	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Cyanosis	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Flush	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Pallor	0 ± 0	2.8 ± 0.1*	2.7 ± 0.2	3 ± 0.1	2.7 ± 0.1	0–4
Palpebral opening	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4 ± 0	4–0

Salivation	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Lacrimation	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Hypohyperthermia	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	– 4/+ 4
Toxicity						
Immediate death	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4
Delayed death (48 h)	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0–4

OX = oxaliplatin; AG = andrographolide; Esc = unloaded escinosomes; AG-Esc = AG-loaded escinosomes